Eli Lilly’s Stock Performance and Estimates for Q3 2018



A look at Eli Lilly

Eli Lilly & Co. (LLY) is a leading US pharmaceutical company with a product portfolio that includes human pharmaceuticals and animal health. The chart below compares the company’s revenues and EPS.

Article continues below advertisement

Stock performance and recommendations

Eli Lilly’s (LLY) stock price has increased ~26.1% in the third quarter, and its stock price rose 27.7% YTD (year-to-date) on October 2. Wall Street analysts expect its stock price to fall ~6.6% over the next 12 months. Analysts’ recommendations show a 12-month target price of $100.73 per share, compared to its October 1 price of $107.60 per share.

Sixteen analysts currently track Eli Lilly stock. Two analysts recommend a “strong buy,” six analysts recommend a “buy,” and eight analysts recommend a “hold.” The consensus rating for Eli Lilly stock stands at 2.38, representing a “buy” for value investors.

Analysts’ revenue estimates

Eli Lilly (LLY) has reported revenue growth in the last several quarters, driven by the increased sales of pharmaceutical products such as Cyramza, Humalog, Jardiance, Taltz, and Trulicity. This revenue growth was partially offset by lower sales of Cymbalta and Zyprexa due to competition from other products.

Analysts expect Eli Lilly to report third-quarter EPS of $1.36 on revenues of $6.0 billion. This represents 6.4% revenue growth, compared to $5.6 billion in the third quarter of 2017.

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) holds 7.8% of its portfolio in Eli Lilly (LLY), 8.6% in Pfizer (PFE), 6.8% in Johnson & Johnson (JNJ), and 4.1% in Allergan (AGN).


More From Market Realist